Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Why Tandem Diabetes (TNDM) Shares Are Trading Lower Today

TNDM Cover Image

What Happened?

Shares of diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) fell 5.5% in the afternoon session after the U.S. government opened an investigation into the national security implications of medical equipment and device imports. 

The Commerce Department initiated a Section 232 investigation that covered a wide range of healthcare products, including items like blood glucose monitors, which are relevant to Tandem's business. This review evaluated U.S. demand, domestic manufacturing capacity, and the impact of imports. A key part of the investigation was to determine if tariffs or quotas should be used to protect national security. This created uncertainty and concern over potential cost increases for medical device companies, impacting investor sentiment.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Tandem Diabetes? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Tandem Diabetes’s shares are extremely volatile and have had 36 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 7 days ago when the stock gained 5% after the company announced the publication of a study showing its automated insulin delivery system was beneficial for adults with type 2 diabetes, while a broader market rally fueled by a Federal Reserve interest rate cut also provided a tailwind. 

The study, published in the American Diabetes Association's Diabetes Care journal, found that the Control-IQ+ system helped adults with insulin-treated type 2 diabetes, regardless of their C-peptide levels. 

This positive news arrived in a favorable market environment. The U.S. Federal Reserve initiated its first interest rate cut of 2025, which buoyed investor sentiment and sent stocks higher for a third straight session. Capital-intensive sectors like biotechnology and healthcare particularly benefited from the signal of improved funding conditions. The specific clinical update, combined with the broader economic tailwind, helped lift the shares.

Tandem Diabetes is down 66.8% since the beginning of the year, and at $11.90 per share, it is trading 73.3% below its 52-week high of $44.64 from September 2024. Investors who bought $1,000 worth of Tandem Diabetes’s shares 5 years ago would now be looking at an investment worth $109.82.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.